BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

292 related articles for article (PubMed ID: 12828493)

  • 1. Cost effectiveness of adding folinic acid to fluorouracil plus levamisole as adjuvant chemotherapy in patients with colon cancer in Germany.
    Monz BU; König HH; Leidl R; Staib L; Link KH
    Pharmacoeconomics; 2003; 21(10):709-19. PubMed ID: 12828493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Capecitabine versus bolus fluorouracil plus leucovorin (folinic acid) as adjuvant chemotherapy for patients with Dukes' C colon cancer : economic evaluation in an Italian NHS setting.
    Di Costanzo F; Ravasio R; Sobrero A; Bertetto O; Vinante O; Luppi G; Labianca R; Amadori D; Barone C; Carlo Merlano M; Longo F; Mansueto G; Antonuzzo L; Gasperoni S
    Clin Drug Investig; 2008; 28(10):645-55. PubMed ID: 18783303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    Smith RD; Hall J; Gurney H; Harnett PR
    Med J Aust; 1993 Mar; 158(5):319-22. PubMed ID: 8474372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacoeconomic analysis of capecitabine versus 5-fluorouracil/leucovorin as adjuvant therapy for stage III colon cancer in Taiwan.
    Hsu TC; Chen HH; Yang MC; Wang HM; Chuang JH; Jao SW; Chiang HC; Wen CY; Tseng JH; Chen LT
    Value Health; 2011; 14(5):647-51. PubMed ID: 21839401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative and cost-effectiveness of oxaliplatin-based or irinotecan-based regimens compared with 5-fluorouracil/leucovorin alone among US elderly stage IV colon cancer patients.
    Mullins CD; Hsiao FY; Onukwugha E; Pandya NB; Hanna N
    Cancer; 2012 Jun; 118(12):3173-81. PubMed ID: 22020739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness analysis of oxaliplatin compared with 5-fluorouracil/leucovorin in adjuvant treatment of stage III colon cancer in the US.
    Aballéa S; Chancellor JV; Raikou M; Drummond MF; Weinstein MC; Jourdan S; Bridgewater J
    Cancer; 2007 Mar; 109(6):1082-9. PubMed ID: 17265519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of adjuvant FOLFOX therapy for stage III colon cancer in Japan based on the MOSAIC trial.
    Shiroiwa T; Takeuchi T; Fukuda T; Shimozuma K; Ohashi Y
    Value Health; 2012; 15(2):255-60. PubMed ID: 22433756
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interferon-alpha in adjuvant treatment of colorectal carcinoma].
    Staib L; Link KH; Henne-Bruns D
    Kongressbd Dtsch Ges Chir Kongr; 2002; 119():142-5. PubMed ID: 12704877
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of capecitabine compared with bolus 5-fluorouracil/l-leucovorin for the adjuvant treatment of colon cancer in Japan.
    Shiroiwa T; Fukuda T; Shimozuma K; Ohashi Y; Tsutani K
    Pharmacoeconomics; 2009; 27(7):597-608. PubMed ID: 19663530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of fluorouracil + folinic acid, fluorouracil + levamisole and fluorouracil + folinic acid + levamisole in Dukes' B and C colon cancer: NSABP Trial C-04].
    Schumacher K
    Strahlenther Onkol; 2000 May; 176(5):239-40. PubMed ID: 10847122
    [No Abstract]   [Full Text] [Related]  

  • 11. Cost-effectiveness analysis of colon cancer treatments from MOSIAC and No. 16968 trials.
    Wen F; Yao K; Du ZD; He XF; Zhang PF; Tang RL; Li Q
    World J Gastroenterol; 2014 Dec; 20(47):17976-84. PubMed ID: 25548497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost effectiveness of adjuvant intraportal chemotherapy in patients with colorectal cancer.
    Messori A; Bonistalli L; Costantini M; Trallori G; Tendi E
    J Clin Gastroenterol; 1996 Dec; 23(4):269-74. PubMed ID: 8957728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis.
    Alarid-Escudero F; Schrag D; Kuntz KM
    Value Health; 2022 Mar; 25(3):409-418. PubMed ID: 35227453
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group.
    Lancet; 2000 May; 355(9215):1588-96. PubMed ID: 10821362
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-utility analysis of adjuvant chemotherapy in patients with stage III colon cancer in Thailand.
    Lerdkiattikorn P; Chaikledkaew U; Lausoontornsiri W; Chindavijak S; Khuhaprema T; Tantai N; Teerawattananon Y
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(4):687-700. PubMed ID: 25327502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cost-utility approach to the use of 5-fluorouracil and levamisole as adjuvant chemotherapy for Dukes' C colonic carcinoma.
    de Souza P
    Med J Aust; 1993 Jun; 158(12):866. PubMed ID: 8326905
    [No Abstract]   [Full Text] [Related]  

  • 17. Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.
    Blohmer JU; Rezai M; Kümmel S; Kühn T; Warm M; Friedrichs K; Benkow A; Valentine WJ; Eiermann W
    J Med Econ; 2013; 16(1):30-40. PubMed ID: 22966753
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes' B2 colon cancer.
    Moertel CG; Fleming TR; Macdonald JS; Haller DG; Laurie JA; Tangen CM; Ungerleider JS; Emerson WA; Tormey DC; Glick JH
    J Clin Oncol; 1995 Dec; 13(12):2936-43. PubMed ID: 8523058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant chemotherapy (5-fluorouracil and levamisole) in Dukes' B and C colorectal carcinoma. A cost-effectiveness analysis.
    Norum J; Vonen B; Olsen JA; Revhaug A
    Ann Oncol; 1997 Jan; 8(1):65-70. PubMed ID: 9093709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adjuvant regional chemotherapy and systemic chemotherapy versus systemic chemotherapy alone in patients with stage II-III colorectal cancer: a multicentre randomised controlled phase III trial.
    Nordlinger B; Rougier P; Arnaud JP; Debois M; Wils J; Ollier JC; Grobost O; Lasser P; Wals J; Lacourt J; Seitz JF; Guimares dos Santos J; Bleiberg H; Mackiewickz R; Conroy T; Bouché O; Morin T; Baila L; van Cutsem E; Bedenne L
    Lancet Oncol; 2005 Jul; 6(7):459-68. PubMed ID: 15992694
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.